Analysts have provided various ratings for Amgen (NASDAQ:AMGN) in the last quarter, with 6 bullish, 4 somewhat bullish, 9 indifferent, and no bearish ratings. Over the past 3 months, 19 analysts have set a 12-month price target for Amgen, averaging $289.95, which is a 4.06% increase from the previous target of $278.64. The high target is $320.00 and the low is $240.00. Analyst ratings are based on predictions of a company's future earnings and revenue, and are updated quarterly or after major company events.